The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a ...

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

CVS reverses Zepbound coverage on commercial formularies after patient backlash and a class-action lawsuit alleging ERISA violations.

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill ...

CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a ...

Eli Lilly (LLY) stock is in focus as CVS Health (CVS) restores Zepbound coverage effective Oct 1, 2026, and adds Foundayo to ...

CVS Caremark, a pharmaceutical distribution center in the Hanover Crossings in Hanover Township, has proposed to expand and build another facility nearly half the size of its current building. CVS ...